Patents by Inventor Ester Fernandez-Salas

Ester Fernandez-Salas has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Chimera Botulinum Toxin Type E
    Publication number: 20100160609
    Abstract: The present invention relates to a toxin comprising a modified light chain of a botulinum toxin type E, wherein the modified light chain comprises amino acid sequence PFVNKQFN (SEQ ID NO: 120) at the N-terminus, and amino acid sequence xDxxxLL (SEQ ID NO: 111) at the C-terminus, wherein x is any amino acid.
    Type: Application
    Filed: January 8, 2010
    Publication date: June 24, 2010
    Inventors: Ester Fernandez-Salas, Lance E. Steward, Todd Herrington, K. Roger Aoki
  • Activatable clostridial toxins
    Patent number: 7740868
    Abstract: Compositions comprising activatable recombinant neurotoxins and polypeptides derived therefrom. The invention also comprises nucleic acids encoding such polypeptides, and methods of making such polypeptides and nucleic acids.
    Type: Grant
    Filed: August 1, 2007
    Date of Patent: June 22, 2010
    Assignee: Allergan, Inc.
    Inventors: Lance E. Steward, Joseph Francis, Ester Fernandez-Salas, Sanjiv Ghanshani, Marcella A. Gilmore, Shengwen Li, J. Oliver Dolly, Kei Roger Aoki
  • FRET PROTEASE ASSAYS FOR CLOSTRIDIAL TOXINS
    Publication number: 20100151494
    Abstract: The present invention provides clostridial toxin substrates useful in assaying for the protease activity of any clostridial toxin, including botulinum toxins of all serotypes as well as tetanus toxins. A clostridial toxin substrate of the invention contains a donor fluorophore; an acceptor having an absorbance spectrum overlapping the emission spectrum of the donor fluorophore; and a clostridial toxin recognition sequence that includes a cleavage site, where the cleavage site intervenes between the donor fluorophore and the acceptor and where, under the appropriate conditions, resonance energy transfer is exhibited between the donor fluorophore and the acceptor.
    Type: Application
    Filed: November 17, 2009
    Publication date: June 17, 2010
    Inventors: Lance E. Steward, Ester Fernandez-Salas, Kei Roger Aoki
  • Fret protease assays for botulinum serotype A/E toxins
    Patent number: 7718766
    Abstract: The present invention provides clostridial toxin substrates useful in assaying for the protease activity of any clostridial toxin, including botulinum toxins of all serotypes as well as tetanus toxins. A clostridial toxin substrate of the invention contains a donor fluorophore; an acceptor having an absorbance spectrum overlapping the emission spectrum of the donor fluorophore; and a clostridial toxin recognition sequence that includes a cleavage site, where the cleavage site intervenes between the donor fluorophore and the acceptor and where, under the appropriate conditions, resonance energy transfer is exhibited between the donor fluorophore and the acceptor.
    Type: Grant
    Filed: October 31, 2008
    Date of Patent: May 18, 2010
    Assignee: Allergan, Inc.
    Inventors: Lance E. Steward, Ester Fernandez-Salas, Kei Roger Aoki
  • CHIMERA BOTULINUM TOXIN TYPE E
    Publication number: 20100121042
    Abstract: The present invention relates to a toxin comprising a modified light chain of a botulinum toxin type E, wherein the modified light chain comprises amino acid sequence PFVNKQFN (SEQ ID NO: 120) at the N-terminus, and amino acid sequence xExxxLL (SEQ ID NO: 112) at the C-terminus, wherein x is any amino acid.
    Type: Application
    Filed: January 8, 2010
    Publication date: May 13, 2010
    Inventors: Ester Fernandez-Salas, Lance E. Steward, Todd Herrington, K. Roger Aoki
  • Substrates useful for FRET protease assays for botulinum serotype A/E toxins
    Patent number: 7709608
    Abstract: The present invention provides clostridial toxin substrates useful in assaying for the protease activity of any clostridial toxin, including botulinum toxins of all serotypes as well as tetanus toxins. A clostridial toxin substrate of the invention contains a donor fluorophore; an acceptor having an absorbance spectrum overlapping the emission spectrum of the donor fluorophore; and a clostridial toxin recognition sequence that includes a cleavage site, where the cleavage site intervenes between the donor fluorophore and the acceptor and where, under the appropriate conditions, resonance energy transfer is exhibited between the donor fluorophore and the acceptor.
    Type: Grant
    Filed: December 11, 2006
    Date of Patent: May 4, 2010
    Assignee: Allergan, Inc.
    Inventors: Lance E. Steward, Ester Fernandez-Salas, Kei Roger Aoki
  • Chimera botulinum toxin type E
    Patent number: 7691983
    Abstract: The present invention relates to a toxin comprising a modified light chain of a botulinum toxin type E, wherein the modified light chain comprises amino acid sequence PFVNKQFN (SEQ ID NO: 120) at the N-terminus, and amino acid sequence xExxxLL (SEQ ID NO: 112) at the C-terminus, wherein x is any amino acid.
    Type: Grant
    Filed: January 14, 2005
    Date of Patent: April 6, 2010
    Assignee: Allergan, Inc.
    Inventors: Ester Fernandez-Salas, Lance E. Steward, Todd Herrington, K. Roger Aoki
  • FRET PROTEASE ASSAYS FOR CLOSTRIDIAL TOXINS
    Publication number: 20100081157
    Abstract: The present invention provides clostridial toxin substrates useful in assaying for the protease activity of any clostridial toxin, including botulinum toxins of all serotypes as well as tetanus toxins. A clostridial toxin substrate of the invention contains a donor fluorophore; an acceptor having an absorbance spectrum overlapping the emission spectrum of the donor fluorophore; and a clostridial toxin recognition sequence that includes a cleavage site, where the cleavage site intervenes between the donor fluorophore and the acceptor and where, under the appropriate conditions, resonance energy transfer is exhibited between the donor fluorophore and the acceptor.
    Type: Application
    Filed: November 17, 2009
    Publication date: April 1, 2010
    Inventors: Lance E. Steward, Ester Fernandez-Salas, Kei Roger Aoki
  • FRET PROTEASE ASSAYS FOR CLOSTRIDIAL TOXINS
    Publication number: 20100081158
    Abstract: The present invention provides clostridial toxin substrates useful in assaying for the protease activity of any clostridial toxin, including botulinum toxins of all serotypes as well as tetanus toxins. A clostridial toxin substrate of the invention contains a donor fluorophore; an acceptor having an absorbance spectrum overlapping the emission spectrum of the donor fluorophore; and a clostridial toxin recognition sequence that includes a cleavage site, where the cleavage site intervenes between the donor fluorophore and the acceptor and where, under the appropriate conditions, resonance energy transfer is exhibited between the donor fluorophore and the acceptor.
    Type: Application
    Filed: November 17, 2009
    Publication date: April 1, 2010
    Inventors: Lance E. Steward, Ester Fernandez-Salas, Kei Roger Aoki
  • FRET PROTEASE ASSAYS FOR CLOSTRIDIAL TOXINS
    Publication number: 20100075346
    Abstract: The present invention provides clostridial toxin substrates useful in assaying for the protease activity of any clostridial toxin, including botulinum toxins of all serotypes as well as tetanus toxins. A clostridial toxin substrate of the invention contains a donor fluorophore; an acceptor having an absorbance spectrum overlapping the emission spectrum of the donor fluorophore; and a clostridial toxin recognition sequence that includes a cleavage site, where the cleavage site intervenes between the donor fluorophore and the acceptor and where, under the appropriate conditions, resonance energy transfer is exhibited between the donor fluorophore and the acceptor.
    Type: Application
    Filed: November 17, 2009
    Publication date: March 25, 2010
    Inventors: Lance E. Steward, Ester Fernandez-Salas, Kei Roger Aoki
  • FRET PROTEASE ASSAYS FOR CLOSTRIDIAL TOXINS
    Publication number: 20100075358
    Abstract: The present invention provides clostridial toxin substrates useful in assaying for the protease activity of any clostridial toxin, including botulinum toxins of all serotypes as well as tetanus toxins. A clostridial toxin substrate of the invention contains a donor fluorophore; an acceptor having an absorbance spectrum overlapping the emission spectrum of the donor fluorophore; and a clostridial toxin recognition sequence that includes a cleavage site, where the cleavage site intervenes between the donor fluorophore and the acceptor and where, under the appropriate conditions, resonance energy transfer is exhibited between the donor fluorophore and the acceptor.
    Type: Application
    Filed: November 17, 2009
    Publication date: March 25, 2010
    Inventors: Lance E. Steward, Ester Fernandez-Salas, Kei Roger Aoki
  • FRET PROTEASE ASSAYS FOR CLOSTRIDIAL TOXINS
    Publication number: 20100075357
    Abstract: The present invention provides clostridial toxin substrates useful in assaying for the protease activity of any clostridial toxin, including botulinum toxins of all serotypes as well as tetanus toxins. A clostridial toxin substrate of the invention contains a donor fluorophore; an acceptor having an absorbance spectrum overlapping the emission spectrum of the donor fluorophore; and a clostridial toxin recognition sequence that includes a cleavage site, where the cleavage site intervenes between the donor fluorophore and the acceptor and where, under the appropriate conditions, resonance energy transfer is exhibited between the donor fluorophore and the acceptor.
    Type: Application
    Filed: November 17, 2009
    Publication date: March 25, 2010
    Inventors: Lance E. Steward, Ester Fernandez-Salas, Kei Roger Aoki
  • SUBSTRATES USEFUL FOR FRET PROTEASE ASSAYS FOR BOTULINUM SEROTYPE A/E TXOINS
    Publication number: 20100069610
    Abstract: The present invention provides clostridial toxin substrates useful in assaying for the protease activity of any clostridial toxin, including botulinum toxins of all serotypes as well as tetanus toxins. A clostridial toxin substrate of the invention contains a donor fluorophore; an acceptor having an absorbance spectrum overlapping the emission spectrum of the donor fluorophore; and a clostridial toxin recognition sequence that includes a cleavage site, where the cleavage site intervenes between the donor fluorophore and the acceptor and where, under the appropriate conditions, resonance energy transfer is exhibited between the donor fluorophore and the acceptor.
    Type: Application
    Filed: December 11, 2006
    Publication date: March 18, 2010
    Applicant: Allergan, Inc.
    Inventors: Lance E. Steward, Ester Fernandez-Salas, Kei Roger Aoki
  • FRET protease assays for botulinum serotype A/E toxins
    Patent number: 7678550
    Abstract: The present invention provides clostridial toxin substrates useful in assaying for the protease activity of any clostridial toxin, including botulinum toxins of all serotypes as well as tetanus toxins. A clostridial toxin substrate of the invention contains a donor fluorophore; an acceptor having an absorbance spectrum overlapping the emission spectrum of the donor fluorophore; and a clostridial toxin recognition sequence that includes a cleavage site, where the cleavage site intervenes between the donor fluorophore and the acceptor and where, under the appropriate conditions, resonance energy transfer is exhibited between the donor fluorophore and the acceptor.
    Type: Grant
    Filed: December 11, 2006
    Date of Patent: March 16, 2010
    Assignee: Allergan, Inc.
    Inventors: Lance E. Steward, Ester Fernandez-Salas, Kei Roger Aoki
  • FRET PROTEASE ASSAYS FOR BOTULINUM SEROTYPE A/E TOXINS
    Publication number: 20100055727
    Abstract: The present invention provides clostridial toxin substrates useful in assaying for the protease activity of any clostridial toxin, including botulinum toxins of all serotypes as well as tetanus toxins. A clostridial toxin substrate of the invention contains a donor fluorophore; an acceptor having an absorbance spectrum overlapping the emission spectrum of the donor fluorophore; and a clostridial toxin recognition sequence that includes a cleavage site, where the cleavage site intervenes between the donor fluorophore and the acceptor and where, under the appropriate conditions, resonance energy transfer is exhibited between the donor fluorophore and the acceptor.
    Type: Application
    Filed: December 11, 2006
    Publication date: March 4, 2010
    Applicant: Allergan, Inc.
    Inventors: LANCE E. STEWARD, Ester Fernandez-Salas, Kei Roger Aoki
  • MODIFIED CLOSTRIDIAL TOXINS WITH ALTERED TARGETING CAPABILITIES FOR CLOSTRIDIAL TOXIN TARGET CELLS
    Publication number: 20100041098
    Abstract: The specification discloses modified Clostridial toxins comprising a Clostridial toxin enzymatic domain, a Clostridial toxin translocation domain and an enhanced Clostridial toxin binding domain; polynucleotide molecules encoding such modified Clostridial toxins; and method of producing such modified Clostridial toxins.
    Type: Application
    Filed: August 15, 2008
    Publication date: February 18, 2010
    Applicant: Allergan, Inc.
    Inventors: Lance E. Steward, Ester Fernandez-Salas, Joseph Francis, Shengwen Li, Marcella A. Gilmore, Kei Roger Aoki
  • Botulinum toxin screening assays
    Patent number: 7645570
    Abstract: Methods for detecting BoNT/A activity in a sample, methods for screening molecules able to compete with BoNT/A receptor binding, methods for reducing BoNT/A activity in a human and methods of marketing a neurotoxin capable of selectively binding to FGFR3 to a governmental or regional regulatory authority.
    Type: Grant
    Filed: March 13, 2008
    Date of Patent: January 12, 2010
    Assignee: Allergan, Inc.
    Inventors: Ester Fernandez-Salas, Patton E. Garay, Kei Roger Aoki
  • BOTULINUM TOXIN SCREENING ASSAYS
    Publication number: 20090317839
    Abstract: Methods for detecting BoNT/A activity in a sample, methods for screening molecules able to compete with BoNT/A receptor binding, methods for reducing BoNT/A activity in a human and methods of marketing a neurotoxin capable of selectively binding to FGFR3 to a governmental or regional regulatory authority.
    Type: Application
    Filed: August 21, 2009
    Publication date: December 24, 2009
    Inventors: Ester Fernandez-Salas, Patton E. Garay, Kei Roger Aoki
  • BOTULINUM TOXIN SCREENING ASSAYS
    Publication number: 20090263836
    Abstract: Methods for detecting BoNT/A activity in a sample, methods for screening molecules able to compete with BoNT/A receptor binding, methods for reducing BoNT/A activity in a human and methods of marketing a neurotoxin capable of selectively binding to a FGFR2, a FGFR3, a SV2, or any combination thereof, to a governmental or regional regulatory authority.
    Type: Application
    Filed: May 20, 2009
    Publication date: October 22, 2009
    Applicant: ALLERGAN, INC.
    Inventors: ESTER FERNANDEZ-SALAS, Birgitte P.S. Jacky, Patton E. Garay, Kei Roger Aoki
  • Botulinum toxin screening assays
    Patent number: 7598027
    Abstract: Methods for detecting BoNT/A activity in a sample, methods for screening molecules able to compete with BoNT/A receptor binding, methods for reducing BoNT/A activity in a human and methods of marketing a neurotoxin capable of selectively binding to FGFR3 to a governmental or regional regulatory authority.
    Type: Grant
    Filed: February 23, 2005
    Date of Patent: October 6, 2009
    Assignee: Allergan, Inc.
    Inventors: Ester Fernandez-Salas, Patton E. Garay, Kei Roger Aoki